dm+d
24406211000001105
Articles
What are the clinically significant drug interactions with tobacco smoking?
23 March 2020This Medicines Q&A summarises those drug interactions with tobacco smoking that are considered to be most clinically important. Most interactions between drugs and tobacco smoking…
Medicine Compliance Aid Stability
AdempasBayer plc
Bayer plc
Adempas
Tablets 500 microgram, 1mg, 1.5mg, 2mg, 2.5mg
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
No special precautions for storage
No special precautions for storage.
9 November 2015
New Medicines
AdempasPulmonary hypertension; arterial (PAH) - in pts not responding to PDE5 inhibitors
Information
Adempas
Licence extension / variation
Bayer
Bayer
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Category
Guanylate cyclase stimulant - first in class
In its pure idiopathic form pulmonary hypertension is a rare disease with an approximate annual incidence of about 1–3 cases per million population.
Pulmonary hypertension; arterial (PAH) - in pts not responding to PDE5 inhibitors
Oral